Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Saved in:
| Title: | Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. |
|---|---|
| Authors: | Radovich M; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Jiang G; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Hancock BA; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Chitambar C; Medical College of Wisconsin, Milwaukee., Nanda R; University of Chicago, Chicago, Illinois., Falkson C; University of Alabama at Birmingham, Birmingham., Lynce FC; Georgetown University, Washington, DC., Gallagher C; Georgetown University, Washington, DC., Isaacs C; Georgetown University, Washington, DC., Blaya M; Memorial Healthcare System, Hollywood, Florida., Paplomata E; Winship Cancer Institute of Emory University, Atlanta, Georgia., Walling R; Community Regional Cancer Care, Indianapolis, Indiana., Daily K; University of Florida, Gainesville., Mahtani R; Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida., Thompson MA; Advocate Aurora Health Care, Milwaukee, Wisconsin., Graham R; Erlanger Health System, Chattanooga, Tennessee., Cooper ME; Foundation Medicine Inc, Cambridge, Massachusetts., Pavlick DC; Foundation Medicine Inc, Cambridge, Massachusetts., Albacker LA; Foundation Medicine Inc, Cambridge, Massachusetts., Gregg J; Foundation Medicine Inc, Cambridge, Massachusetts.; University of California at Davis, Davis., Solzak JP; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Chen YH; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Bales CL; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Cantor E; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Shen F; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Storniolo AMV; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Badve S; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Ballinger TJ; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Chang CL; Purdue University School of Mechanical Engineering, West Lafayette, Indiana., Zhong Y; Purdue University School of Mechanical Engineering, West Lafayette, Indiana., Savran C; Purdue University School of Mechanical Engineering, West Lafayette, Indiana., Miller KD; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis., Schneider BP; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis. |
| Source: | JAMA oncology [JAMA Oncol] 2020 Sep 01; Vol. 6 (9), pp. 1410-1415. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
